Sera Prognostics
Women's health company dedicated to improving maternal and neonatal health by providing innovative pregnancy biomarker tests. Publicly traded on NASDAQ (SERA). Developed PreTRM test for predicting preterm birth risk.
Notes
Sera Prognostics is a women's health company dedicated to improving maternal and neonatal health by providing innovative pregnancy biomarker information to physicians. The company is publicly traded on NASDAQ under the ticker symbol SERA and is headquartered in Salt Lake City, Utah.
The company's flagship product is the PreTRM test, a blood test that can predict a pregnant woman's risk of spontaneous preterm birth. Preterm birth is the leading cause of infant mortality and can lead to long-term health complications. Early identification of at-risk pregnancies enables proactive interventions to improve outcomes.
Sera Prognostics' technology platform analyzes biomarkers in maternal blood to provide predictive insights about pregnancy complications.
Team
- Gregory C. Critchfield, M.D., M.S. - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/gregorycritchfield
- Jay Moyes - Chief Financial Officer
- Angela Bianco, M.D. - Chief Medical Officer
Additional Research Findings
- NASDAQ: SERA (publicly traded)
- Portfolio company of aMoon
- PreTRM test for preterm birth prediction
- Focus on pregnancy complications prediction
- Maternal and neonatal health focus
- Salt Lake City, Utah headquarters
- Founded in 2008
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| aMoon | Tel Aviv, Israel | biotech-focused | series-aseries-b+2 | 8 |